| Schedule of Reportable Segment Loss |
The following table presents reportable segment loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Chronic cough in IPF clinical trial expense |
|
$ |
4,347 |
|
|
$ |
3,039 |
|
|
$ |
6,034 |
|
|
$ |
5,921 |
|
Refractory chronic cough clinical trial expense |
|
|
2,028 |
|
|
|
434 |
|
|
|
3,106 |
|
|
|
1,252 |
|
Clinical trial material |
|
|
2,351 |
|
|
|
330 |
|
|
|
3,904 |
|
|
|
564 |
|
Other clinical trials and studies 1 |
|
|
1,144 |
|
|
|
1,269 |
|
|
|
2,443 |
|
|
|
1,317 |
|
Other clinical development expenses 2 |
|
|
1,848 |
|
|
|
1,861 |
|
|
|
3,371 |
|
|
|
3,279 |
|
Employee compensation (excluding stock compensation expense) |
|
|
3,347 |
|
|
|
2,818 |
|
|
|
6,506 |
|
|
|
5,775 |
|
Stock-based compensation expense |
|
|
3,272 |
|
|
|
1,384 |
|
|
|
5,463 |
|
|
|
2,592 |
|
Other segment items 3 |
|
|
2,156 |
|
|
|
2,573 |
|
|
|
4,554 |
|
|
|
4,473 |
|
Interest income, net |
|
|
(2,696 |
) |
|
|
(1,407 |
) |
|
|
(4,392 |
) |
|
|
(2,532 |
) |
Net loss |
|
$ |
17,797 |
|
|
$ |
12,301 |
|
|
$ |
30,989 |
|
|
$ |
22,641 |
|
(1) Includes expense related to the Company’s Phase 1 NDA supportive studies (2) Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance. (3) Includes general administrative expense, other (expense) income, net and income tax benefit.
|